Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

Published:2018-04 Issue:4 Volume:16 Page:558-566.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Bril Fernando,Kalavalapalli Srilaxmi,Clark Virginia C.,Lomonaco Romina,Soldevila-Pico Consuelo,Liu I-Chia,Orsak Beverly,Tio Fermin,Cusi Kenneth

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference23 articles.

1. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus;Bril;Endocrinol Metab Clin North Am,2016

2. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States;Wong;Gastroenterology,2015

3. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies;Wang;Int J Cancer,2012

4. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action;Bril;Diabetes Care,2017

5. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial;Cusi;Ann Intern Med,2016

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD;Diabetes Research and Clinical Practice;2024-08

2. Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives;International Journal of Pharmaceutics;2024-07

3. Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping;World Journal of Gastrointestinal Pathophysiology;2024-05-24

4. Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2024-05-02

5. Challenges and opportunities in obesity: the role of adipocytes during tissue fibrosis;Frontiers in Endocrinology;2024-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3